Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nope.
Bottom line is BIIB still has lipstick on a pig.
Anavex possibly could have Blarcamesine denied for Alzheimer’s. Lucky for them, it isn’t a one hit wonder.
Did you mention that to BIIB? They sure thought it was
So if he were to get the data on both candidates, which one do you think he would take? Data being what’s available from BIIB and Anavex currently.
Yes Bas,
typical look at what I got in this hand(Paid articles of how BIIB will get favorable reviews today) , while the real show is in the other hand.(taking attention away from a REAL cns candidate)
What will BIIB do when the pdd data gets released, or when Rett results/data gets released, or dots connecting how certain cns diseases are similar, or.......
You get the point.
Biogen can only pump that failure so much times and time IS running out for them.
Next time we hear about Biogen and Alzheimer’s should now be what....., March?
Curious where Anavex will be trials wise.
Well, if you look at how much BIIB gained over the past 2 days.....that is a lot of funds that could easily prop up or bring down their competition. Especially ones with a small MC. Not saying that is what happened.
Next week we shall see if any of the insiders that knew Biogen wouldn’t get favorable news and sold during the pump.....will buy AVXL on the cheap.
Poor BIIB bag holders that bought on the run up.
I bet buffet is out of his BIIB shares. Any takers
With Rett results lurking in the background.....
What I’ve noticed about the board over the years is that there’s over expectation as far as what is actually released. Then after the fact the criticisms begin.
Just kick back, relax, and let Missling execute his vision.
Can’t stand playing the long game........there’s a ton more get rich quick schemes.
It’s been 5 years since Anavex rang the closing bell, or was it the opening......?
THEY called it quits. IT failed. Doesn’t matter how many people were enrolled. They should have to confirm their fake positivity found but we’ll see what deep pockets can buy tomorrow.
So simple when you analyze after failure right.
Could you imagine if Anavex tried that.....the crap the Cramers or Adams of the world would give them.
I was saying as of Nov 2, they are still scheduled to present on Nov 6 @ 11am. So they haven’t been pulled for some made up reasoning ppl may come up with.
https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
They are in the program as of Oct 23
LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life Sciences - New York, NY (United States)
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
No one seems to think it a coincidence Anavex got a slot for LB at CTAD after BIIB will go to the FDA advisory meeting to discuss the BLA within hours of each other with their joke of a candidate?
Last year it was BIIB lying to steal Anavex thunder.........
This year......
What’s the time difference?
And if BIIB gets their candidate approved next month?
COVID-19 Might Increase Risk of Memory Loss and Cognitive Decline
https://www.discovermagazine.com/health/how-covid-19-might-increase-risk-of-memory-loss-and-cognitive-decline
If A-273 does get approved for any indication, what’s the chances of doctors prescribing a-273 for the above?
What other treatment plans is there for neurological damage covid leaves behind.
Another dot connected. How long ago was it that the topic of the day on the board was the gut?
https://www.yahoo.com/news/researchers-study-between-gut-health-213618194.html
When’s the cover by date for shorts?
CDC Taps Alzheimer’s Association to Lead National Effort to Slash Dementia Risk
https://alzheimersnewstoday.com/2020/09/28/cdc-taps-alzheimers-association-to-lead-national-effort-to-slash-dementia-risk/
Guess someone could call HR, find out and report back.
Not sure if this one is being tracked:
Protein Misfolding Drug Discovery Summit
When:
Oct. 27 2020
Where:
The Westin Copley Place
10 Huntington Ave Boston, MA 02116
Speaking:
Christopher Missling President and CEO Anavex Life Sciences
https://boston.eventful.com/events/protein-misfolding-drug-di-/E0-001-133314844-0@2020102709
Or paid
What’s this for? Most people here were owned stock ALREADY when this happened. What’s next, the high of $15 soon after the up listing?
Economy won’t recover in Hawaii as we still have stay at home till May 31.
Doesn’t mean tourists aren’t showing up and disregarding the 14 day quarantine.
Luckily, I’m an essential worker outside of the food and tourist industry
THAT is just as much a false statement as saying Eisai hired him to help with the collaboration between Eisai and Anavex.
BOTTOM line, no one knows so best bet is to just keep quiet and reflect 10 years from now.
Just shows how much confidence they have in their smoke and mirror trick they pulled late last year.
Berkshire bought 648,000 shares worth $192M of BIIB. To think how much more he would have profited had he invested in AVXL is crazy
We aren’t even close to what the pps should be. $10-$15 is more where it should be trading.
The street is starting to take notice, FINALLY.
Between Anavex and BIIB, which would be the more riskier pick for a successful ALZ treatment.
Disappointing to see that the DIAN trial looking into the efficacy of gantenerumab and solanezumab to slow familial #Alzheimer's disease did not meet its primary endpoints
https://t.co/b8BCj1xPF0
That wouldn’t happen to be the p3 trial that they stopped and threw in the towel is it? Then they did a newly discovered equation and walla......they are now trying to get back in the game saying the patients DID improve.... look at my new cherry picked data it doesn’t LIE........
Nice post Jimmy. Finally someone that took what I was thinking about valuation of companies and put it all on paper.
If top line for Rett, PDD is positive you can bet ALZ patients as well as Drs will want to see if they or their patients qualify for the P2/3 trial
Cuttlefish, my favorite
“It looks as though when naturally-occurring genetic variants reduce the activity of tyrosine phosphatases then this makes Alzheimer's disease less likely to develop, suggesting drugs which have the same effect might also be protective.”
https://www.yahoo.com/news/genetic-mutations-that-may-protect-against-alzheimers-discovered-by-scientists-000149026.html
Or BIIB attempt to get back in the Alzheimer’s field
How about possibly kicking yourself years later for selling way to early
You say disappointed with the result, I say disappointed they couldn’t hammer out a license on the cheap.
Bottom line ......either/or could be correct.
NOBODY else knows besides the 2 companies.
Biogen to buy experimental Alzheimer's, Parkinson's treatment from Pfizer for $75M plus incentives
There they go again.
https://www.yahoo.com/finance/news/biogen-buy-experimental-alzheimer-apos-144544214.html
With whom he has to work with in the states to get this approved he is doing just fine. Most any other ceo would have put this co under water